Shandong Xinhua Pharmaceutical Co Ltd banner

Shandong Xinhua Pharmaceutical Co Ltd
SZSE:000756

Watchlist Manager
Shandong Xinhua Pharmaceutical Co Ltd Logo
Shandong Xinhua Pharmaceutical Co Ltd
SZSE:000756
Watchlist
Price: 14.36 CNY -0.97% Market Closed
Market Cap: ¥9.9B

Shandong Xinhua Pharmaceutical Co Ltd
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Shandong Xinhua Pharmaceutical Co Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Shandong Xinhua Pharmaceutical Co Ltd
SZSE:000756
Revenue
¥8.8B
CAGR 3-Years
5%
CAGR 5-Years
8%
CAGR 10-Years
9%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Revenue
¥15B
CAGR 3-Years
17%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Revenue
¥32.6B
CAGR 3-Years
15%
CAGR 5-Years
2%
CAGR 10-Years
13%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Revenue
¥41.2B
CAGR 3-Years
4%
CAGR 5-Years
5%
CAGR 10-Years
7%
Zhejiang Nhu Co Ltd
SZSE:002001
Revenue
¥22.3B
CAGR 3-Years
12%
CAGR 5-Years
17%
CAGR 10-Years
19%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Revenue
¥5.8B
CAGR 3-Years
94%
CAGR 5-Years
37%
CAGR 10-Years
N/A
No Stocks Found

Shandong Xinhua Pharmaceutical Co Ltd
Glance View

Market Cap
9.9B CNY
Industry
Pharmaceuticals

In the industrious province of Shandong, China, Shandong Xinhua Pharmaceutical Co. Ltd. emerges as a notable player in the pharmaceutical landscape. Established in 1943, the company has grown into a comprehensive pharmaceutical enterprise with a significant presence both domestically and internationally. At its core, Shandong Xinhua is devoted to the research, development, and manufacture of active pharmaceutical ingredients (APIs), finished dosages, and chemical intermediates. The firm's strength lies in its diverse range of products, with pain management and anti-infectives being standout categories. Their strategic focus on innovation is evident in their state-of-the-art R&D facilities, which fuel continuous product development, ensuring they meet high regulatory standards and cater to evolving market demands. The journey of Shandong Xinhua is one of strategic evolution, with a steadfast commitment to quality and sustainability. This narrative is reflected in their robust revenue streams derived from both domestic sales and the lucrative export markets across over 50 countries. The company's business model hinges on creating value through efficient manufacturing processes and leveraging economies of scale, which enhances their competitive edge in the global market. With an eye on future growth, they've also been investing in digitalization to streamline operations and enhance productivity. As the pharmaceutical sector continues to expand, Shandong Xinhua Pharmaceutical Co. Ltd. is poised to capitalize on emerging opportunities, underpinned by its solid foundation and innovative thrust.

Intrinsic Value
16.75 CNY
Undervaluation 14%
Intrinsic Value
Price ¥14.36

See Also

What is Shandong Xinhua Pharmaceutical Co Ltd's Revenue?
Revenue
8.8B CNY

Based on the financial report for Dec 31, 2025, Shandong Xinhua Pharmaceutical Co Ltd's Revenue amounts to 8.8B CNY.

What is Shandong Xinhua Pharmaceutical Co Ltd's Revenue growth rate?
Revenue CAGR 10Y
9%

Over the last year, the Revenue growth was 3%. The average annual Revenue growth rates for Shandong Xinhua Pharmaceutical Co Ltd have been 5% over the past three years , 8% over the past five years , and 9% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett